Multimodal high-throughput analysis with -omics technologies for the comprehensive molecular characterization of neoplasms has become a standard procedure in experimental biology. Currently, however, it is not clear how the novel biological knowledge and the new methodologies can be translated into a real world clinical setting in the context of the often overstressed „personalization“ of modern patient treatment. Therefore the question whether the "genomic revolution" in basic science will be mirrored by a corresponding clinical revolution still remains unanswered. In this talk concepts, strategies and pitfalls in the translation of -omics data and technologies into clinical reality will be presented and discussed.